 | |
| Company type | Public |
|---|---|
| Nasdaq: MYGN S&P 600 Component | |
| Industry | Healthcare Molecular Diagnostics Biotechnology Precision Medicine |
| Founded | 1991, in Salt Lake City, Utah, United States |
| Founder | Mark Skolnick Peter Meldrum |
| Headquarters | Salt Lake City, Utah |
Key people | Paul J. Diaz (president and CEO) Jerry Lanchbury (CSO) Walter Gilbert (director and vice chair) |
| Revenue |  $690.6 Million(2021)[1] |
Number of employees | 2,600[2] |
| Website | myriad |
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (precision medicine), assess a patient's risk of disease progression and disease recurrence (precision medicine), and measure disease activity.